Gamida Cell Ltd. (GMDA)
| Previous close | 0.0327 |
| Open | 0.0395 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0327 - 0.0327 |
| 52-week range | 0.0080 - 2.5100 |
| Volume | |
| Avg. volume | 9,670,277 |
| Market cap | 4.337M |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8200 |
| Earnings date | 25 Mar 2024 - 29 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
GlobeNewswireXORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail “Abbey” L. Jenkins, M.S.,
GlobeNewswireAquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct
- Thomson Reuters StreetEvents
Q4 2023 Gamida Cell Ltd Earnings Call
Q4 2023 Gamida Cell Ltd Earnings Call
